Otsuka To Submit NDA For Tuberculosis Drug Delamanid, A First In 50 Years In Japan
This article was originally published in PharmAsia News
Executive Summary
Otsuka will apply for the approval of the tuberculosis drug Delamanid (OPC-67683) for treatment of multi-drug resistant TB in Japan later this month, the company announced March 27.